Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells

Cell Growth and Differentiation

Volumn 7, Issue 11, 1996, Pages 1507-1512

  Basu, Alakananda ^a   Weixel, Kelly ^a   Saijo, Nagahiro ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; PHORBOL DIBUTYRATE; PROTEIN KINASE C;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BLEOMYCIN; CARCINOMA; CARCINOMA, SMALL CELL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ETOPOSIDE; FEMALE; HEAD AND NECK NEOPLASMS; HERPES SIMPLEX VIRUS PROTEIN VMW65; HUMANS; LACTONES; LUNG NEOPLASMS; MACROLIDES; OVARIAN NEOPLASMS; PACLITAXEL; PHORBOL 12,13-DIBUTYRATE; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0029956761     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Saijo, N. Combined modality therapy for small cell lung cancer. Oncology, 49 (Suppl. 1): 2-10, 1992.
2. 2{d(pGpG)}. Science (Washington DC), 230: 412-417, 1985.
3. Chu, G. Cellular responses to cisplatin: the roles of DNA-binding proteins and DNA repair. J. Biol. Chem., 269: 787-790, 1994.
4. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor), 2: 275-279, 1990.
5. Basu, A., Teicher, B. A., and Lazo, J. S. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J. Biol. Chem., 265: 8451-8457, 1990.
6. Basu, A., Kozikowski, A. P., Sato, K., and Lazo, J. S. Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogs of protein kinase C activator lyngbyatoxin A. Cancer Res., 51: 2511-2514, 1991.
7. Basu, A., and Lazo, J. S. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res., 52: 3119-3124, 1992.
8. Basu, A., and Cline, J. Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int. J. Cancer, 63: 597-603, 1995.
9. Basu, A., and Weixel, K. M. Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int. J. Cancer, 62: 457-460, 1995.
10. Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Uberall, F., and Grunicke, H. H. Enhancement of the antiproliferative activity of cis-diamminedichloroplainum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42: 382-388, 1988.
11. Isonishi, S., Andrews, P. A., and Howell, S. B. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem., 265: 3623-3627, 1990.
12. Basu, A., Burke, K., Cline, J., and Saijo, N. Protein kinase C and cisplatin resistance. J. Cell. Biochem., 18D (Suppl.): 93, 1994.
13. Basu, A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol. & Ther., 59: 257-280, 1993.
14. Johannes, F-J., Prestle, J., Eis, S., Oberhagemann, P., and Pfizenmaier, K. PKCμ is a novel, atypical member of the protein kinase C family. J. Biol. Chem., 269: 6140-6148, 1994.
15. Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., Matsuda, T., and Saijo, N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 51: 3237-3242, 1991.
16. Basu, A., and Evans, R. W. Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II). Int. J. Cancer, 58: 587-591, 1994.
17. Minato, K., Kanzawa, F., Nishio, K., Nakagawa, K., Fujiwara, Y., and Saijo, N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother. Pharmacol., 26: 313-317, 1990.
18. Ohta, S., Nishio, K., Kubato, N., Ohmori, T., Funayama, Y., Ohira, T., Nakajima, H., Adachi, M., and Saijo, N. Characterization of a Taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res., 85: 290-297, 1994.
19. Blobel, G. C., Sachs, C. W., Khan, W. A., Fabbro, D., Stabel, S., Wetsel, W. C., Obeid, L. M., Fine, R. L., and Hannun, Y. A. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells: functional significance of enhanced expression of PKCα. J. Biol. Chem., 268: 658-664, 1993.
20. Ritke, M. K., Murray, N. R., Allan, W. P., Fields, A. P., and Yalowich, J. C. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of β II protein kinase C. Mol. Pharmacol., 48: 798-805, 1995.